News Life and Health02 Aug 2018

China:ZhongAn in health tech partnership

| 02 Aug 2018

China's first online only insurer, ZhongAn, has formed a partnership with Boston-based biotech company Orig3n to offer health tech solutions to Chinese consumers.

ZhongAn will now supplement its insurance offerings with healthcare solutions including a suite of DNA tests to their extensive customer base of nearly 500 million people, and to the China market as a whole. The product suite is backed by Orig3n's extensive knowledge of genetic testing applications, being one of the leading US direct-to-consumer DNA test platforms.

The two companies also agree to establish a new laboratory in Shanghai, which focuses on the application and innovation of healthcare technologies. Locating the lab in Shanghai will also enable the companies to provide Chinese consumers with personalised, efficient and convenient healthcare solutions.

Orig3n provides consumers direct, affordable access to information about their lifestyle-related genes, thereby empowering people to make educated, proactive and personalised lifestyle choices that may impact their well-being. Orig3n also invests in breakthrough cell therapy programmes by utilising cutting-edge cellular science to develop personalised therapies for repairing tissue damage and treating disease. Since its inception in 2014, Orig3n has built the largest suite of direct-to-consumer genetic tests on the market, and the world's most comprehensive cell bank for commercial regenerative medicine applications.

ZhongAn started operations in October 2013. The company primarily offers products and solutions in the context of five major ecosystems, namely lifestyle consumption, consumer finance, health, auto, and travel.

| Print | Share

CAPTCHA image
Enter the code shown above in the box below.

Note that your comment may be edited or removed in the future, and that your comment may appear alongside the original article on websites other than this one.

 

Recent Comments

There are no comments submitted yet. Do you have an interesting opinion? Then be the first to post a comment.

Other News



Follow Asia Insurance Review